Stonegate Investment Group’s IN8bio INAB Stock Holding History

Stonegate Investment Group’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,000	Closed	-$29.9K	–	454
2025 Q1	$29.9K	Hold	6,000	–	–	﹤0.01%	367
2024 Q4	$46.3K	Hold	6,000	–	–	﹤0.01%	354
2024 Q3	$48.6K	Hold	6,000	–	–	﹤0.01%	365
2024 Q2	$152K	Hold	6,000	–	–	﹤0.01%	341
2024 Q1	$212K	Hold	6,000	–	–	0.01%	307
2023 Q4	$248K	Hold	6,000	–	–	0.01%	268
2023 Q3	$187K	Hold	6,000	–	–	0.01%	282
2023 Q2	$277K	Sell	6,000 -1,744	-23%	-$109K	0.01%	261
2023 Q1	$302K	Hold	7,744	–	–	0.01%	249
2022 Q4	$537K	Hold	7,744	–	–	0.02%	197
2022 Q3	$469K	Sell	7,744 -1,139	-13%	-$76.5K	0.02%	189
2022 Q2	$602K	Buy	+8,883	New	+$751K	0.03%	171

Other funds holding INAB

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Stonegate Investment Group's INAB Position: Q2 2025 in Review

Stonegate Investment Group sold out of IN8bio (INAB) in Q2 2025, closing a stake of 6,000 shares — an estimated $29.9K sold.

Stonegate Investment Group first reported a position in INAB in Q2 2022 and held it in 12 quarters. The position peaked at $602K in Q2 2022. 12 funds tracked by Wall St. Rank hold INAB as of Q2 2025.

Stonegate Investment Group reported no remaining IN8bio position as of Q2 2025 after selling out during the quarter.
Stonegate Investment Group sold 6,000 IN8bio shares in Q2 2025, an estimated $29.9K.
Stonegate Investment Group first reported a position in IN8bio in Q2 2022 and held it in 12 quarters.
Stonegate Investment Group's IN8bio position peaked at $602K in Q2 2022.
12 funds tracked by Wall St. Rank held IN8bio as of Q2 2025.

Based on Stonegate Investment Group's 13F filing for Q2 2025, filed 23 Jul 2025.